Sutro Biopharma STRO Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's operating income?
- Sutro Biopharma (STRO) reported operating income of -$29.66M in Q1 2026.
- How has Sutro Biopharma's operating income changed year-over-year?
- Sutro Biopharma's operating income increased by 56.7% year-over-year, from -$68.51M to -$29.66M.
- What is the long-term trend for Sutro Biopharma's operating income?
- Over 3 years (2021 to 2025), Sutro Biopharma's operating income has grown at a 17.1% compound annual growth rate (CAGR), from -$98.52M to -$158.37M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.